GENB

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies toward wet-lab capability and experienced development scientists, and much of that talent is concentrated in Greater Bost

Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive $30M upfront, up to $35M in early preclinical milestones, and a total of up to nearly $1.2B in milestones, plus tiered royalties for two initial programs, with an option to add a third The agreement will broaden Zealand Pharma’s modality capabilities beyond peptides while extending The Generate Platform into obesity and other metabolic diseases SOMERVILLE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced a m

Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functionsGenerate will receive USD 30 million up-front, up to USD 35 million in early preclinical milestones, and a total of nearly USD 1.2 billion in milestones, plus tiered royalties for two initial programs, with an option to add a thirdThe agreement will broaden Zealand Pharma’s modality capabilities beyond peptides

Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswell Park Treatment is designed to avoid pre-infusion chemotherapy and its side effects GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors BUFFALO, N.Y. and SOMERVILLE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Roswell Park Comprehensive Cancer Center ("Roswell Park") and Generate Biomedicines, Inc. ("Generate") today announced that the first patient has been dosed in a first-in-human clinical trial evaluating GB-5267, an investigational, autologous

SOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced that members of its management team will participate in presentations at the following investor conferences: Cantor Global Healthcare Conference, New York, NY: Wednesday, Sept. 9 at 3:55 p.m. ET  Morgan Stanley 24th Annual Global Healthcare Conference, New York, NY: Monday, Sept. 14 at 7:00 a.m. ET  Goldman Sachs Life Sciences Symposium, New York, NY: Tuesday, Sept. 15 at 9:05 a.m. ETH.C. Wainwright 28th Annual Global Investment Conference, New York, NY: Wednesday, Sept. 16 at 10:30 a.m. ET  Bernstein Insights Healthcare Leaders and Disruptors, New York, NY: Wednesda

4 - Generate Biomedicines, Inc. (0002100782) (Issuer)

144 - Generate Biomedicines, Inc. (0002100782) (Subject)

144 - Generate Biomedicines, Inc. (0002100782) (Subject)

8-K - Generate Biomedicines, Inc. (0002100782) (Filer)

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8 All patients enrolled in first cohort of the Phase 1 study for GB-4362 (MMAE neutralizer) Platform advancements extend across strategic collaborations Approximately $457.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026 SOMERVILLE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today reported financial results for the seco

8-K - Generate Biomedicines, Inc. (0002100782) (Filer)

10-Q - Generate Biomedicines, Inc. (0002100782) (Filer)

Newly Constructed Phase 2 now 100% LeasedFurther Solidifies Innovation Park as Boston's Premier Advanced Manufacturing DestinationBOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced that AdvanCell has signed a long-term ~128,000 square foot lease for the entire 1 Corporate Drive building at Innovation Park, IQHQ's premier life science and advanced manufacturing campus in Andover, Massachusetts. The transaction is one of the largest life science leases in Greater Boston this year and brings the newly constructed Phase 2 of Innovation Park to 100% leased. AdvanCell's decision to locate at Innovation Park after a broad search and competitive process underscores the strength of the

SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ:GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026. A live webcast is expected to be available in the Events and Presentations section of the Company's investor website at investors.generatebiomedicines.com. An archived replay is also expected to be available following the presentation.About Generate:BiomedicinesGenerate (NASDAQ:GENB) is a clinical-stage generative biology company founded at the intersection of machine le

SCHEDULE 13G - Generate Biomedicines, Inc. (0002100782) (Subject)

SCHEDULE 13G - Generate Biomedicines, Inc. (0002100782) (Subject)

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advanceClinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026 SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ:GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026,

10-Q - Generate Biomedicines, Inc. (0002100782) (Filer)

8-K - Generate Biomedicines, Inc. (0002100782) (Filer)

H.C. Wainwright initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $16.00

Piper Sandler initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $24.00

Morgan Stanley initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $20.00

Cantor Fitzgerald initiated coverage of Generate Biomedicines with a rating of Overweight

Guggenheim initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $30.00

Goldman initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $26.00